Study Of Thrombotic Thrombocytopenic Purpura Medicine Demonstrates Safety

Patient Worthy Contributor

Caplacizumab is a medicine that has been developed to treat acquired thrombotic thrombocytopenic purpura (TTP). TTP causes serious symptoms. such as thrombocytopenia, a condition in which a patient doesn’t have enough platelets. A recent Phase I study observed both Caucasian and Japanese participants, and found that the treatment did not show adverse effects in either group.

Read the original article on Globe Newswire here.

Are you waiting for an treatment for a rare disease? Share your feelings and stories with the Patient Worthy community!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Study Of Thrombotic Thrombocytopenic Purpura Medicine Demonstrates Safety

Patient Worthy Contributor

Are you waiting for an treatment for a rare disease? Share your feelings and stories with the Patient Worthy community!

Patient Worthy Contributor

Metastatic Breast Cancer: Navigating Grief

Rethinking What It Means to Live With Acromegaly

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

Let’s Work Together!

Keep Up to Date

Learn More